Reprieve is a medical technology company developing a diuretic treatment device for acute decompensated heart failure (ADHF) patients.
reprievecardio.com
Milford, MA
CEO: Mark Pacyna
Arboretum Lead: Jan Garfinkle
Reprieve Cardiovascular
IN THE NEWS
First-In-Human Study Demonstrates the Potential of the Reprieve System in Patients with Acute Decompensated Heart Failure
Reprieve Cardiovascular, Inc., a development-stage company focused on advancing acute decompensated heart failure (ADHF) treatment, today announced the first-in-human results of the Reprieve System at the CSI Focus D-HF (Device…
Read More
Reprieve Completes Randomized Trial for Heart Failure
Reprieve Cardiovascular, Inc., a development-stage company pioneering an intelligent automated diuretic and fluid management approach for acute decompensated heart failure (ADHF) treatment, today announced the completion of enrollment in the…
Read More
Reprieve Cardiovascular Partners with Leading Heart Failure Researchers and Truveta to Analyze Real-World Heart Failure Patient Data
Reprieve Cardiovascular, Inc. (‘Reprieve’), a development stage company focused on pioneering an intelligent approach to acute decompensated heart failure (ADHF) treatment, today highlighted the publication of TREAT-AHF study results in JACC: Heart…
Read More
